Company profile: Sionna Therapeutics
1.1 - Company Overview
Company description
- Provider of small molecule therapies for cystic fibrosis, including SION-638, an NBD1 stabilizer in Phase 1 clinical trials designed to restore CFTR function; SION-109, a small molecule targeting the ICL4–NBD1 interface, in Phase 1; and SION-719, a second series NBD1 stabilizer in preclinical development.
Products and services
- SION-109: Clinical-stage small molecule targeting the CFTR protein’s ICL4–NBD1 interface, currently in Phase 1 trials, intended to treat cystic fibrosis by precisely engaging that domain interface
- SION-638: Clinical-stage small molecule NBD1 stabilizer in Phase 1 trials, engineered to restore CFTR function by stabilizing the CFTR protein’s NBD1 domain for cystic fibrosis treatment
- SION-719: Preclinical-stage second-series small molecule NBD1 stabilizer engineered to restore CFTR function by stabilizing the CFTR protein’s NBD1 domain for cystic fibrosis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sionna Therapeutics
CandidRx
HQ: United States
Website
- Description: Provider of T-cell engager and bispecific antibody therapeutics for autoimmune diseases, developing candidates that redirect T cells to eliminate autoreactive B cells for deeper depletion. Pipeline includes CND106 (BCMAxCD3), a bispecific targeting BCMA and CD3 to remove autoantibody-producing B cells, and CND261 (CD20xCD3), a bispecific targeting CD20 and CD3 to address a broad range of B-cell subtypes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CandidRx company profile →
Principia Biopharma
HQ: United States
Website
- Description: Provider of pre-clinical discovery and development of differentiated oral small-molecule therapies for inflammatory and autoimmune diseases and cancer, addressing significant unmet medical needs in immunology and oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Principia Biopharma company profile →
ARS Pharma
HQ: United States
Website
- Description: Provider of pharmaceutical research and development specializing in anti-allergy drugs; operates as a stealth pharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ARS Pharma company profile →
Alladapt
HQ: United States
Website
- Description: Provider of prescription therapeutics targeting food allergy; a privately held biopharmaceutical company focused on developing such treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alladapt company profile →
Epirus Biopharma
HQ: United States
Website
- Description: Provider of biosimilar monoclonal antibodies and therapeutic proteins for emerging markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epirus Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sionna Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sionna Therapeutics
2.2 - Growth funds investing in similar companies to Sionna Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sionna Therapeutics
4.2 - Public trading comparable groups for Sionna Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →